Antibiotics in burn patients;ANTIBIOTIKATHERAPIE VON INFEKTIONEN BEI VERBRENNUNGSPATIENTEN

Acta Chirurgica Austriaca

Volumn 29, Issue 6, 1997, Pages 325-330

  Presterl, Elisabeth ^a   Diem, E ^b   Graninger, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Antibiotic therapy; Burns; Infections; Speciman sampling

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; FLUCLOXACILLIN; FLUCONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFADIAZINE SILVER; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BLOOD CULTURE; BURN; CANDIDIASIS; COLITIS; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFECTION RISK; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOSIS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS; TOPICAL DRUG ADMINISTRATION; URINARY TRACT INFECTION;

EID: 0031405322     PISSN: 0001544X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02619900     Document Type: Article

References (37)

1. Arturson G: Neutrophil granulocyte functions in severely burned patients. Burns 987;11:309-319.
2. Bourget P, Lsene-Hulin A, Le-Reveille R, Le-Bever H, Carsin H: Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996;40:139-145.
3. Brater DC, Bawdon RE, Anderson SA, Purdue GF, Hunt JL: Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986;39:631-634.
4. Desai MH, Herndon DN, Abston S: Candida infection in massively burned patients. J Trauma 1987;27:1186-1188.
5. Diem E: Klinik und Therapie der Verbrennungssepsis. Wien, Maudrich, 1990.
6. Donati L, Periti P: Antibiotic treatment of burned patients: an Italian multi-centre study. Intensive Care Med 1994;20:30-34.
7. Eaves-Pyles T, Alexander JW: Granulocyte colony-stimulating factor enhances killing of translocated bacteria but does not affect barrier function in burn mouse model. J Trauma 1996;41:1013-1017.
8. Frame JD, Kangsu L, Malik WM: Changing flora in burn and trauma units: experience in the United Kingdom. J Burn Care Rehabil 1992;13:281-286.
9. Frieden TR, Munsiff SS, Low DB, Willey BM, Williams G, Faur Y, Eisner W, Warren S, Kreiswirth B: Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342:76-79.
10. Garrelts JC, Jost G, Kowalsky SF, Kroö GJ, Lettieri JT: Ciprofloxacin pharmacokinetics in burn patients. Antimicrob Agents Chemother 1996;40:1153-1156.
11. Graninger W, Diem E, Meissl G: Bakterielles Erregerspektrum und Chemotherapie bei der Sepsis des Brandverletzten. Klin Anästh Intensivther 1982;25:133-142.
12. Hoey LL, Tschida SJ, Rotschafer JC, Guay DR, Vance-Bryan K: Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil 1997;18:116-124.
13. Horton JW: Bacterial translocatin after burn injury: the contribution of ischemia and permability changes. Shock 1994;1:286-290.
14. Hunt JL, Purdue GF: The elderly burn patient. Am J Surg 1992;164:472-476.
15. Jones WG, Barie S, Yurt RW, Goodwin CW: Enterococcal burn sepsis. Arch Surg 1986;121:649-653.
16. Kealey GP, Chang P, Heinle J, Rosenquist MD, Lewis RW: Prospective comparison of two management strategics of central venous catheters in burn patients. J Trauma Injury Infect Crit Care 1995;38:344-349.
17. Kealey GP, Heinle JA, Lewis RW, Pfaller MA, Rosenquist MD: Value of the Candida antigen assay in diagnosis of systemic candidiasis in burn patients. J Trauma 1992;32:285-288.
18. Liechtenstein A, Margalit P: Liposome-encapsulated silver sulfadiazine (SSD) for topical treatment of infected burns: thermodynamics of drug encapsulation and kinetics of drug release. J Inorg Biochem 1995;60:187-198.
19. Loirat P, Rohan J, Bailett A, Beaufils F, David R, Chapman A: Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Eng J Med 1978;299:915-919.
20. Lyytikainen O, Koljalg S, Harma M, Vuopio-Varkila J: Outbreak caused by two Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. J Hosp Infect 1995;31:41-54.
21. McManus WF, Goodwin CW, Pruitt BA: Subeschar treatment of burn-wound infection. Arch Surg 1983;118:291-294.
22. Merrell SW, Saffle JR, Larson CM, Sullivan JJ: The declining incidence of fatal sepsis following thermal injury. J Trauma 1989;29:1362-1366.
23. Miller C, Baker CC: Changes in lymphocyte activity after thermal injury. J Clin Invest 1979;63:202-210.
24. Phillips LG, Heggers JP, Robson MC: Burn and trauma units as sources of methicillin-resistant Staphylococcus aureus. J Burn Care Rehabil 1992;13:293-297.
25. Presterl E, Laßnigg A, Willinger B, Granniger W: Candida-Infektionen in der Intensivmedizin. Anaesthesist 1996;45:195-210.
26. Sartorelli KH, Silver GM, Gamelle RL: The effect of granulocyte-stimulating factor (G-CSF) upon burn-induced defective neutrophil chemotaxis. J Trauma 1991;31:523-529.
27. Sasaki TM, Welch GW, Herndon DN: Burn-wound manipulation-induced bacteremia. J Trauma 1979;19:46-48.
28. Sittig K, Deitch EA: Effect of bacteremia on mortality after thermal injury. Arch Surg 1988;123:1367-1370.
29. Smith DJ jr, Thomson PD: Changing flora in burn and trauma units: historical perspective - experience in the United States. J Burn Care Rehabil 1992;13:276-280.
30. Spera RV, Farber BF: Multidrug-resistant Enterococcus faecium. An untreatable nosocomial pathogen. Drugs 1994;48:678-688.
31. Steer JA, Papni RP, Wilson AP, MvGrouther DA, Parkhouse N: Quantitave microbiology in the management of burn patients. I. Correlation between quantitative and qualitative burn wound biopsy culture and surface alginate culture. Burns 1996;22:173-176.
32. Steer JA, Papini RP, Wilson AP, McGrouther DA, Parkhouse N: Quantitative microbiology in the management of burn patients. II. Relationship between bacterial counts obtained by burn wound biopsy culture and surface alginate swab culture, with clinical outcome following burn surgery and change of dressing. Burns 1996;22:177-181.
33. Stratta RJ, Glenn DW: Immune parameters in burned patients: Effect and therapeutic interventions. J Trauma 1986;26:7-17.
34. Tilley PA, Roberts FJ: Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis 1994;18:896-900.
35. Vindenes H, Bjerkes R: Microbial colonization of large wounds. Burns 1995;21:575-579.
36. Vindenes H, Bjerkes R: The frequency of bacteremia and fungemia following wound cleaning and excision in patients with large burn wounds. J Trauma 1993;35:742-749.
37. Zaske DE, Sawchuk RJ, Gerding DN, Strate RG: Increased dosage requirements of gentamicin in burn patients. J Trauma 1976;16:824-828.